Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WuXi Biologics

Division of WuXi PharmaTech Inc.
www.wuxibiologics.com

Latest From WuXi Biologics

Deal Watch: Millendo Completes Merger With OvaScience, With $85m In Bank For Two Mid-Stage Programs

OvaScience’s cash plus a $49.5m venture capital raise leave Millendo with more than enough to get two current programs to data readouts in early 2020, company says. AMAG merges with Perosphere, adding to its hematology business.

Deals Business Strategies

Brii Builds China Ops With Hep B Assets, New Partnerships

China-focused Brii Biosciences, formed earlier this year, unveils plans to take its first projects into the clinic by way of deals with VBI and Vir for hepatitis B, and builds other alliances and operations in the country.

China Commercial

Novartis And MSD Triumph At The 14th Annual Scrip Awards

The pharma, biotech and allied industries came together to celebrate another year of excellence at the 14th Annual Scrip awards in London on Nov. 28, hosted by the Right Honourable Lord (William) Hague.

Commercial Leadership

Asia Deal Watch: FujiFilm, Hisun Team To Develop Flu Drug For Chinese Market

Agreement between FujiFilm and Hisun sets plan for developing the novel flu drug Avigan in China. Also, CANbridge and WuXi partner in rare diseases, and Kissei gets Asian rights to Rigel’s Tavalisse.

Asia Pacific Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • WuXi PharmaTech Inc.
  • Senior Management
  • Chris Chen, PhD, CEO
    Weichang Zhou, PhD, CTO
  • Contact Info
  • WuXi Biologics
    Phone: 400 820 0985
    288 Fute Zhong Rd.
    Waigaoqiao FTZ
    Shanghai, 200131
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register